Last reviewed · How we verify
Thrombocytopenic disorder
Approved treatments
- Mulpleta · Vancocin Italia
Mulpleta works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow. - Doptelet · Akarx Inc
Doptelet works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Thrombocytopenic disorder patent landscape — cliff calendar, originator estates, attackable patents
- Thrombocytopenic disorder treatment landscape brief
- Thrombocytopenic disorder treatment updates RSS
Frequently asked questions about Thrombocytopenic disorder
What drugs treat Thrombocytopenic disorder?
Tracked treatments include Mulpleta, Doptelet.
What is the treatment for Thrombocytopenic disorder?
Standard treatment for Thrombocytopenic disorder includes Mulpleta, Doptelet. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Thrombocytopenic disorder patent cliff · Thrombocytopenic disorder CI report
- Treatment: Mulpleta · Vancocin Italia
- Treatment: Doptelet · Akarx Inc
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing